Skip to content

Efficacy Analysis of Combined Repetitive Transcranial Magnetic Stimulation Neuroregulation and Xixin Yizhi Decoction in the Treatment of Alzheimer's Disease and Its Effect on Tau Protein Phosphorylation Levels

Efficacy Analysis of Combined Repetitive Transcranial Magnetic Stimulation Neuroregulation and Xixin Yizhi Decoction in the Treatment of Alzheimer's Disease and Its Effect on Tau Protein Phosphorylation Levels

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000904
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-17
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

rTMS control group:MagproR30 rTMS device, 10Hz frequency, 80% motor threshold, bilateral DLPFC stimulation, 3 times/week for 8 weeks.
Xixin Yizhi Decoction group:Oral administration of Xixin Yizhi Decoction, one dose daily (divided into two servings), for 8 consecutive weeks.
Combined therapy group:Receive both rTMS treatment and oral Xixin Yizhi Decoction simultaneously for 8 weeks.

Sponsors

Hunan Provincial Rehabilitation Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Aged 50 to 85 years; 2.Meet the clinical diagnostic criteria for Alzheimer's disease according to the International Working Group (IWG) 2007 criteria; 3.Traditional Chinese Medicine (TCM) pattern differentiation of "Marrow Sea Deficiency with Phlegm Turbidity Obstructing the Orifices"; 4.Mini-Mental State Examination (MMSE) score consistent with mild to moderate cognitive impairment (illiterate: 10–17; primary school education: 10–20; secondary school education or above: 10–26); 5.Magnetic Resonance Imaging (MRI) showing atrophy of the hippocampus or medial temporal lobe; 6.Medial Temporal Lobe Atrophy (MTA-scale) score meeting the criteria (=2 for age <75 years, =3 for age =75 years); 7.Voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Other types of dementia or psychiatric disorders; Severe cardiac, hepatic, or renal dysfunction; Use of a cardiac pacemaker or recent acupuncture treatment (e.g., within the past 4 weeks); Allergy to electrical stimulation or current use of anticoagulant therapy.

Design outcomes

Primary

MeasureTime frame
Alzheimer's Disease Assessment Scale - Cognitive Subscale Score;

Secondary

MeasureTime frame
Mini-Mental State Examination Score;Activities of Daily Living Scale Score;Peripheral Blood Phosphorylated Tau Protein (p-tau181) Level;Peripheral Blood Total Tau Protein (t-tau) Level;

Countries

China

Contacts

Public Contactzhang jianyun

Hunan Provincial Rehabilitation Hospital

2890906948@qq.com15074831619

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026